Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard fist-line systemic treatment, compared to continued standard first-line systemic treatment in patients with unresectable oligometastatic CRC.

Primary Sponsor

AGITG

Collaborating Groups

TROG Cancer Research

Participating Centres

Accrual Target

74

Current Accrual

Trial Chairperson

Dr Julie Chu

Trial Contact

qa@trog.com.au

Related Post

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a

June 15, 2021

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery

Ductal carcinoma in situ (DCIS) of the breast is

Skip to toolbar